Hagop Kantarjian Selected Research

Disease Progression

4/2023	Targeting MCL1-driven anti-apoptotic pathways to overcome hypomethylating agent resistance in RAS -mutated chronic myelomonocytic leukemia.
12/2021	Phase II study of single-agent nivolumab in patients with myelofibrosis.
4/2018	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
3/2018	Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
6/2017	Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
5/2017	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
1/2017	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
12/2016	KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.
9/2014	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
10/2013	Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hagop Kantarjian Research Topics

Disease

223	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 04/2024 - 01/2000
205	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2024 - 01/2002
128	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/2024 - 03/2002
123	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 03/2024 - 01/2002
123	Neoplasms (Cancer) 02/2024 - 01/2002
123	Leukemia 12/2023 - 03/2002
85	Philadelphia Chromosome 04/2024 - 02/2002
40	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 03/2002
39	Primary Myelofibrosis (Myelosclerosis) 04/2024 - 09/2002
34	Hematologic Neoplasms (Hematological Malignancy) 05/2023 - 01/2002
28	Acute Promyelocytic Leukemia 02/2024 - 05/2003
25	Thrombocytopenia (Thrombopenia) 04/2023 - 04/2004
25	Blast Crisis (Blast Phase) 01/2023 - 10/2002
24	Residual Neoplasm 12/2022 - 11/2006
22	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 04/2023 - 06/2002
18	Infections 11/2023 - 03/2003
18	Disease Progression 04/2023 - 05/2002
18	Anemia 01/2023 - 03/2002
18	Myeloid Leukemia (Leukemia, Myelocytic) 01/2021 - 04/2006
16	Chromosome Aberrations (Chromosome Abnormalities) 01/2023 - 05/2002
15	Lymphoma (Lymphomas) 01/2022 - 06/2005
12	Neutropenia 04/2024 - 09/2003
12	Splenomegaly 04/2024 - 03/2002
12	Pneumonia (Pneumonitis) 01/2024 - 01/2003
11	Exanthema (Rash) 11/2023 - 06/2009
11	Myeloproliferative Disorders (Myeloproliferative Disorder) 06/2008 - 09/2002
10	Multiple Myeloma 10/2017 - 03/2003
10	Polycythemia Vera 04/2017 - 06/2003
9	Nausea 11/2023 - 10/2002
9	Hemorrhage 01/2023 - 06/2009
9	Pathologic Complete Response 07/2020 - 01/2003
9	Hypereosinophilic Syndrome (Loeffler Endocarditis) 06/2013 - 09/2002
8	Fever (Fevers) 11/2023 - 01/2003
8	Hypertension (High Blood Pressure) 01/2023 - 01/2011
7	Sepsis (Septicemia) 01/2024 - 08/2004
7	Cytopenia 11/2022 - 06/2007
7	Diarrhea 01/2017 - 12/2003
7	Systemic Mastocytosis 09/2013 - 05/2004
7	Essential Thrombocythemia 08/2013 - 01/2003
6	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2024 - 03/2003

Drug/Important Bio-Agent (IBA)

149	Imatinib Mesylate (Gleevec)FDA Link 12/2023 - 01/2000
96	Tyrosine Kinase InhibitorsIBA 03/2024 - 11/2006
62	Cytarabine (Cytosar-U)FDA LinkGeneric 04/2024 - 03/2002
41	Dasatinib (BMS 354825)FDA Link 04/2024 - 06/2006
41	Decitabine FDA Link 02/2024 - 03/2003
32	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2002
30	Phosphotransferases (Kinase)IBA 01/2023 - 12/2003
28	Azacitidine (5 Azacytidine)FDA Link 01/2024 - 01/2005
25	fludarabineIBA 01/2023 - 03/2003
24	venetoclaxIBA 04/2024 - 03/2014
23	Inotuzumab OzogamicinIBA 05/2024 - 06/2013
23	ponatinibIBA 04/2024 - 11/2012
23	Rituximab (Mabthera)FDA Link 12/2021 - 11/2003
23	nilotinib FDA Link 03/2016 - 07/2005
22	bcr-abl Fusion ProteinsIBA 01/2022 - 01/2000
21	blinatumomabIBA 02/2024 - 01/2017
21	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2021 - 03/2002
21	Monoclonal AntibodiesIBA 01/2021 - 09/2004
20	Arsenic Trioxide (Trisenox)FDA Link 02/2024 - 05/2003
19	Clofarabine (Clolar)FDA Link 01/2021 - 10/2003
18	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 03/2002
17	Tretinoin (Retinoic Acid)FDA LinkGeneric 02/2024 - 05/2003
17	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 11/2023 - 01/2003
15	Gemtuzumab (Mylotarg)FDA Link 11/2022 - 01/2002
15	InterferonsIBA 01/2021 - 03/2003
14	ruxolitinibIBA 01/2023 - 04/2010
13	Biomarkers (Surrogate Marker)IBA 04/2024 - 06/2002
13	ibrutinibIBA 01/2023 - 06/2014
13	Core Binding Factors (Core-Binding Factor)IBA 01/2023 - 12/2008
13	Interferon-alpha (Interferon Alfa)IBA 06/2012 - 01/2000
12	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 03/2003
12	DNA (Deoxyribonucleic Acid)IBA 01/2024 - 12/2003
12	Dexamethasone (Maxidex)FDA LinkGeneric 10/2021 - 03/2002
12	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 03/2002
10	Sorafenib (BAY 43-9006)FDA Link 11/2023 - 12/2008
10	Lenalidomide (CC 5013)FDA Link 10/2022 - 05/2007
10	Hemoglobins (Hemoglobin)IBA 07/2018 - 06/2004
9	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 12/2023 - 03/2002
9	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 06/2014
9	CytokinesIBA 12/2021 - 09/2002
9	fms-Like Tyrosine Kinase 3IBA 01/2020 - 05/2004
8	Alkylating AgentsIBA 02/2024 - 05/2004
8	BilirubinIBA 12/2023 - 04/2012
8	Indicators and Reagents (Reagents)IBA 12/2023 - 05/2006
8	Alemtuzumab (Campath)FDA Link 06/2013 - 11/2005
7	CreatinineIBA 12/2023 - 10/2008
7	HomoharringtonineIBA 01/2019 - 01/2007
7	Prednisone (Sone)FDA LinkGeneric 12/2018 - 09/2010
7	Methotrexate (Mexate)FDA LinkGeneric 01/2016 - 03/2002
7	tipifarnib (R115777)IBA 03/2011 - 10/2002

Therapy/Procedure

315	Therapeutics 04/2024 - 03/2002
113	Drug Therapy (Chemotherapy) 04/2024 - 03/2002
26	Stem Cell Transplantation 01/2024 - 07/2003
21	Salvage Therapy 01/2023 - 04/2003
15	Hematopoietic Stem Cell Transplantation 02/2024 - 02/2007
15	Induction Chemotherapy 12/2023 - 01/2003
8	Transplantation 01/2022 - 09/2003
7	Cell Transplantation 11/2022 - 01/2007
7	Drug Tapering 11/2020 - 12/2003
6	Immunotherapy 10/2023 - 12/2016